Weight Loss Tablets Instead of Injections: What the Evidence Now Shows

What the OASIS 4 trial actually found, and how to read the numbers

When the MHRA approved Wegovy tablets in June 2026, it did so on the basis of the OASIS 4 phase 3 trial: 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, followed for 64 weeks alongside lifestyle changes. The headline figure (around 13.6% average weight loss compared with roughly 2.4% on placebo) is the intention-to-treat result, meaning it counts everyone who started the trial, including those who did not complete it. Among participants who stayed fully adherent, average weight loss reached approximately 17%. Both figures are worth knowing. The intention-to-treat number is the more conservative, real-world estimate; the adherence number shows what the medicine can do when taken consistently. Side effects were predominantly gastrointestinal: nausea, vomiting and similar symptoms affected around 74% of the oral semaglutide group, compared with 42% on placebo. Most were mild to moderate and settled as the body adjusted. The comparison between tablets and injections in terms of efficacy is more nuanced than a single figure suggests, and understanding the trial design helps.

For context, the STEP 1 trial of weekly semaglutide 2.4mg injections (Wegovy) reported approximately 15% average weight loss over 68 weeks, as published in the New England Journal of Medicine. The injection maintains slightly higher average results; the tablet closes much of that gap and adds meaningful practical advantages for people who would otherwise avoid treatment altogether because of needle anxiety, and anyone weighing up whether weight loss pills could work for them instead of injections will find a detailed breakdown of those trade-offs worth reading.

Who the tablet is licensed for, and what the prescription process involves

The Wegovy tablet is licensed for adults with a BMI of 30 or above, or a BMI between 27 and 29.9 alongside at least one weight-related health condition, for example, high blood pressure, raised cholesterol, prediabetes or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance. A BMI figure alone does not determine whether treatment is right for you; the prescriber looks at your full health picture, including any contraindications and current medicines. The tablet is not licensed for use in pregnancy, during breastfeeding, or for those trying to conceive. It is not licensed for under-18s.

The dosing schedule starts at 1.5mg once daily and escalates through 4mg and 9mg to a 25mg maintenance dose, with at least one month at each level. The titration exists to give the body time to adjust, which is why gastrointestinal side effects tend to ease as treatment progresses. Your prescriber decides the pace, not a fixed calendar. People already established on the 2.4mg weekly injection may, subject to clinical assessment, move directly to the 25mg tablet, though that decision sits with the prescribing clinician. Exact dosing detail is in the Wegovy tablet SmPC on the eMC, which is the authoritative reference.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day it is submitted. If you are curious about the clinical team behind those assessments, our lead prescriber's profile is on the site.

Practical differences between taking a tablet and using an injection pen

This is where many people find the tablet genuinely changes what treatment feels like day to day. There is no pen to refrigerate, no needle to change, no injection site to rotate. The tablet goes in a bag or pocket. One practical habit worth building in the first week: before you put the kettle on in the morning, take the tablet with a small glass of plain water, then wait at least 30 minutes before eating, drinking coffee or taking any other oral medicines. That sequence is straightforward once it becomes routine, but getting it wrong in the early weeks can reduce absorption.

The injection pens are not without their own practical advantages, once-weekly dosing means six fewer days of remembering. Some people find a weekly rhythm easier than a daily one. If needle anxiety is not a factor for you, whether tablets or injections suit you better comes down to lifestyle, health profile and clinical assessment rather than a simple ranking. The Mounjaro injection, for example, is a dual GIP and GLP-1 receptor agonist (the only dual-agonist weight-loss medicine licensed in the UK) and the SURMOUNT-1 trial reported average weight reductions of around 20–21% at the highest dose. That is a meaningful clinical difference, and it is one a prescriber will discuss with you.

For a fuller look at what private treatment costs across the different formats, the weight loss injections cost page covers the market context honestly, including what transparent pricing should include.

What the NHS covers and where private treatment fits in

The Wegovy tablet had no NICE technology appraisal at the time of its MHRA approval in June 2026, which means it is not available on the NHS at this stage, a NICE appraisal process would need to conclude first. The Wegovy injection is available through NHS specialist weight management services under NICE TA875, though waiting lists are commonly long and eligibility criteria are strict. Mounjaro (tirzepatide) injections are being rolled out on the NHS under NICE TA1026, phased by BMI and the number of qualifying health conditions, with GP prescribing becoming possible from April 2026 under an updated GP contract.

If you do not meet current NHS criteria, or prefer not to wait, a private prescription through a regulated online pharmacy is the legal alternative. Verify any pharmacy you are considering on the GPhC register before sharing health information or making a payment. Medicines sold for weight loss without a clinical assessment are not a safer or cheaper version of the same thing, they are a different risk category entirely. The MHRA's Yellow Card scheme lets you report both suspected side effects and suspect sellers, and it is worth knowing that route exists. For a broader overview of all the treatment options currently available, the weight loss treatments page is a good starting point.